EGFR inhibitors for treating keratodermas
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Assistance Publique-HôPitaux De Paris (Aphp), Universite De Paris, Fondation Imagine, Universite Paris-Sud
InventorsChristine Bodemer, Céline Greco, Claude Boucheix
Life of this patent
Estimating the term…
Abstract
Olmsted syndrome (OS) is a rare genodermatosis classically characterized by the combination of bilateral mutilating transgredient palmoplantar keratoderma (PPK) and periorificial keratotic plaques. The inventors obtained remarkable results with a treatment with a EGFR inhibitor (e.g. erlotinib) in 3 patients with Olmsted Syndrome and erythemalgia linked to different TRPV3 mutations. In less than 3 months, the drug induced a complete disappearance of the hyperkeratosis and the pain. Anorexia and insomnia disappeared with an improvement of the growth. Accordingly, the present invention relates to the use of EGFR inhibitors for the keratodermas.
Claims11
A method of treating Olmsted syndrome in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an epithelial growth factor receptor (EGFR) inhibitor, wherein said patient harbors at least one transient receptor potential vanilloid-3 (TRPV3) mutation, and wherein said patient also suffers from erythromelalgia.
Dependencies are inferred from the claim text.